

Biocon Biologics to expand biosimilar oncology portfolio

08 January 2026 | News

Proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®)



Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio.

The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, to be held from Jan 12 to Jan 15, 2026.

The company is set to unveil three new biosimilar oncology assets—Trastuzumab/Hyaluronidase (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®)—at the 2026 J.P. Morgan Healthcare Conference. With these new oncology assets, including two PD-1 inhibitors, Biocon Biologics will have one of the most comprehensive oncology portfolios in the industry. This will enable the company to broaden the availability of critical oncology therapies through cost-effective biosimilar alternatives.

Global sales of Keytruda were \$29.5 billion in 2024; Opdivo sales in 2024 were \$9.3 billion; and Herceptin SC and Herceptin HYLECTA combined sales were \$1.72 billion in 2024. These new assets are among the largest oncology biologics scheduled to lose exclusivity over the next five years and will join Biocon Biologics' existing portfolio of 17 oncology medications, which includes Pertuzumab (Perjeta®) that was recently submitted to the FDA, as well as several small molecule cancer therapies. The company's oncology portfolio, including undisclosed products, represents an over \$75 billion opportunity, or approximately 35% of the global oncology pharmaceutical market.